Charles Schwab Investment Management Inc. Has $18.04 Million Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Charles Schwab Investment Management Inc. boosted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 2.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 195,752 shares of the medical instruments supplier's stock after buying an additional 4,241 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.87% of LeMaitre Vascular worth $18,037,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its stake in LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 293 shares in the last quarter. KBC Group NV lifted its holdings in shares of LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after acquiring an additional 410 shares during the last quarter. Empowered Funds LLC bought a new position in shares of LeMaitre Vascular in the fourth quarter worth about $150,000. SG Americas Securities LLC bought a new position in shares of LeMaitre Vascular in the fourth quarter worth about $158,000. Finally, Advisors Asset Management Inc. lifted its holdings in shares of LeMaitre Vascular by 180.2% in the third quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier's stock worth $172,000 after acquiring an additional 1,191 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

LMAT has been the subject of a number of research reports. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price for the company. Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Lake Street Capital raised their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a report on Friday, February 28th. Finally, Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $95.25.

Insider Buying and Selling at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. This trade represents a 26.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 10.79% of the company's stock.

LeMaitre Vascular Trading Down 2.6 %

NASDAQ:LMAT traded down $2.19 on Friday, reaching $83.49. 1,117,137 shares of the stock traded hands, compared to its average volume of 148,281. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of 45.62, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. The company's 50 day moving average is $94.32 and its 200-day moving average is $94.47. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting analysts' consensus estimates of $0.49. The business had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. On average, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date is Thursday, March 13th. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's dividend payout ratio is currently 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.